IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

IOL Chemicals & Pharmaceuticals Ltd

₹ 445 1.73%
26 May - close price
iolcp.com BSE: 524164 NSE : IOLCP
About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Key Points

Pharma Segment - APIs (~46% of revenues) [1]
The company manufactures various APIs for various therapeutic areas such as Pain management, anti-diabetic, anti-platelet, anti-cholesterol and others. It is the largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share. [2] In FY22, Ibuprofen accounted for ~65% of revenues of the company's pharma segment.

Website BSE NSE
  • Market Cap ₹ 2,611 Cr.
  • Current Price ₹ 445
  • High / Low ₹ 463 / 272
  • Stock P/E 18.6
  • Book Value ₹ 257
  • Dividend Yield 0.90 %
  • ROCE 13.6 %
  • ROE 9.66 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 20.0%
  • Promoter holding has increased by 4.50% over last quarter.

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
441 460 533 513 460 519 538 555 572 565 541 523 587
305 308 362 356 349 408 494 496 529 509 510 480 491
Operating Profit 137 152 171 157 111 110 44 59 43 56 32 43 96
OPM % 31% 33% 32% 31% 24% 21% 8% 11% 8% 10% 6% 8% 16%
5 6 4 8 6 -8 11 9 7 5 5 7 9
Interest 3 2 1 1 1 2 2 2 2 3 4 5 5
Depreciation 9 9 10 10 10 10 11 11 11 11 11 12 12
Profit before tax 130 147 165 154 106 90 42 55 37 47 22 33 88
Tax % 31% 13% 23% 25% 29% 25% 26% 27% 24% 25% 28% 27% 25%
Net Profit 90 128 127 115 75 67 31 40 28 35 16 24 65
EPS in Rs 15.87 21.73 21.63 19.56 12.82 11.41 5.25 6.83 4.73 5.94 2.67 4.11 11.12
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
471 482 564 385 580 711 983 1,685 1,894 1,967 2,184 2,217
402 392 468 373 529 608 863 1,276 1,321 1,375 1,927 1,991
Operating Profit 69 89 96 11 51 102 120 410 574 592 257 227
OPM % 15% 18% 17% 3% 9% 14% 12% 24% 30% 30% 12% 10%
2 3 1 1 1 1 6 10 16 24 17 26
Interest 43 57 60 59 61 68 64 51 21 6 8 16
Depreciation 24 31 32 29 30 30 30 32 36 39 43 46
Profit before tax 4 3 5 -75 -39 6 31 336 533 571 223 189
Tax % -25% 46% 35% 12% -4% 21% 12% 30% 32% 22% 26% 26%
Net Profit 5 2 3 -67 -40 5 28 237 361 445 166 140
EPS in Rs 1.85 0.61 1.15 -13.99 -7.12 0.83 4.93 41.61 63.51 75.73 28.22 23.84
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 5% 8% 14% 17%
Compounded Sales Growth
10 Years: 17%
5 Years: 18%
3 Years: 5%
TTM: 2%
Compounded Profit Growth
10 Years: 56%
5 Years: 38%
3 Years: -27%
TTM: -21%
Stock Price CAGR
10 Years: 36%
5 Years: 35%
3 Years: 6%
1 Year: 19%
Return on Equity
10 Years: 22%
5 Years: 28%
3 Years: 20%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
31 31 49 48 56 56 56 57 57 59 59 59
Reserves 143 142 160 154 129 132 160 408 747 1,202 1,332 1,448
394 400 357 400 453 447 422 284 59 3 44 80
124 159 195 100 135 182 214 193 306 347 526 434
Total Liabilities 687 727 741 702 772 817 852 942 1,170 1,610 1,960 2,021
462 430 411 403 400 374 406 412 469 512 561 760
CWIP 12 32 33 4 4 21 7 27 19 48 105 81
Investments 0 0 0 0 0 0 0 0 0 1 2 20
213 265 297 295 369 422 439 503 682 1,048 1,292 1,159
Total Assets 687 727 741 702 772 817 852 942 1,170 1,610 1,960 2,021

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
55 53 78 -47 18 83 120 273 471 380 91 123
-87 -18 -12 -5 -27 -23 -50 -63 -184 -317 -120 -119
23 -32 -66 50 9 -60 -70 -197 -272 -58 -2 -4
Net Cash Flow -9 3 1 -2 -0 1 -1 13 15 4 -31 -0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 17 27 32 31 55 58 54 43 52 56 79 83
Inventory Days 160 199 190 279 201 201 109 66 64 98 95 77
Days Payable 97 116 119 92 102 115 83 42 62 79 95 74
Cash Conversion Cycle 80 110 103 218 154 144 80 67 55 74 79 86
Working Capital Days 32 82 58 173 125 108 73 57 57 66 78 86
ROCE % 9% 11% 11% -3% 4% 12% 15% 56% 69% 54% 18% 14%

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
43.69 43.69 43.69 43.69 43.69 43.69 43.69 43.69 43.69 43.69 43.69 48.19
6.47 6.40 7.77 5.96 5.05 2.76 3.03 3.14 2.50 2.41 2.37 2.43
0.25 0.02 0.06 0.06 0.04 0.36 0.51 0.04 0.04 0.05 0.16 0.23
49.59 49.89 48.48 50.29 51.21 53.18 52.77 53.13 53.77 53.84 53.78 49.15

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls